Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revenge Of The "Brain-Dead Kangaroos": Many Veterans Of 2007 Avandia Vote Come Down Harder On Drug In 2010

Executive Summary

Accumulating negative information about the cardiovascular risks of GlaxoSmithKline's type 2 diabetes drug Avandia (rosiglitazone) led a much larger number of FDA advisory panel members to recommend taking it off the market than when the same committees met three years earlier

You may also be interested in...



Avandia Advisory Committee Sees New Role For REMS As Research Tool

FDA advisory committee members who favor continued availability of GlaxoSmithKline's Avandia (rosiglitazone) with a Risk Evaluation and Mitigation Strategy seem to be hopeful the new regulatory tool can be used for an even broader purpose - providing answers needed to justify keeping the drug on the market

Avandia Advisory Committee Sees New Role For REMS As Research Tool

FDA advisory committee members who favor continued availability of GlaxoSmithKline's Avandia (rosiglitazone) with a Risk Evaluation and Mitigation Strategy seem to be hopeful the new regulatory tool can be used for an even broader purpose - providing answers needed to justify keeping the drug on the market

FDA's Marciniak vs. Unger: Cardio Experts Divided On GSK's RECORD Study

FDA's internal disagreements about the value of GlaxoSmithKline's RECORD trial stem, in part, from different visions of the role agency reviewers should play in analyzing data

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel